Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis

Journal of Clinical Investigation

Volumn 99, Issue 8, 1997, Pages 1966-1973

  Sevransky, Jonathan E ^a   Shaked, Gade ^a   Novogrodsky, Abraham ^b   Levitzki, Alexander ^c   Gazit, Aviv ^c   Hoffman, Amnon ^c   Elin, Ronald J ^a   Quezado, Zenaide M N ^a   Freeman, Bradley D ^a   Eichacker, Peter Q ^a   Danner, Robert L ^a   Banks, Steven M ^a   Bacher, John ^a   Thomas III, Marvin L ^a   Natanson, Charles ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

cell signaling pathways; multiorgan failure; septic shock; tyrosine kinase inhibitor

Indexed keywords

N (4 BUTYLPHENYL) ALPHA CYANOCAFFEIC ACID AMIDE; TYRPHOSTIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BACTERIAL PERITONITIS; CONTROLLED STUDY; DOG; DRUG EFFECT; ESCHERICHIA COLI; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK; SURVIVAL;

EID: 0030903743     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119364     Document Type: Article

References (39)

1. Natanson, C., W.D. Hoffman, A.F. Suffredini, P.Q. Eichacker, and R.L. Danner. 1994. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann. Intern. Med. 120:771-783.
2. Center for Disease Control. 1990. Increase in national hospital discharge survey rates for septicemia - United States 1979-1987. MMWR (Morb. Mort. Wkly Rep.). 39:31-34.
3. Abraham, E., R. Wunderink, H. Silverman, T.M. Perl, S. Nasraway, H. Levy, R. Bone, R. Wenzel, R. Balk, R. Allred, J.E. Pennington, and J.C. Wherry. 1995. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. JAMA. 273:934-941.
4. Fisher, C.J., J.M. Agosti, S.M. Opal, S.F. Lowry, R.A. Balk, J.C. Sadoff, E. Abraham, R.M.H. Schein, and E. Benjamen. 1996. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N. Engl. J. Med. 334:1697-1702.
5. McCloskey, R.V., R.C. Straub, R.C. Sanders, S.M. Smith, and C.R. Smith. 1994. Treatment of septic shock with human monoclonal antibody HA-1A. Ann. Intern. Med. 121:1-5.
6. Fisher, C.J., S.M. Opal, J.F. Dhainaut, S. Stephans, J.L. Zimmerman, P. Nightingale, S.J. Harris, R.M. Schein, E.A. Panacek, C. Garrard, et al. 1993. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit. Care. Med. 21:318-327.
7. Fisher, C.J., J.F. Dhainaut, S.M. Opal, J.P. Pribble, R.A. Balk, G.J. Slotman, T.J. Iberti, E.C. Rackow, M.J. Shapiro, R.L. Greenman, et al. 1994. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind placebo-controlled trial. JAMA 271:1836-1843.
8. Tracey, K.J., Y. Fong, D.G. Hesse, K.R. Manogue, A.T. Lee, G.C. Kuo, S.I. Lowry, and A. Cerami. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (Lond.). 330:662-664.
9. Ohlsson, K., P. Bjork, M. Bergenfeldt, R. Hageman, and R.C. Thompson. 1990. IL-1 receptor antagonist reduces mortality from endotoxin shock. Nature (Lond.). 348:550-552.
10. Teng, N.N.H., H.S. Kaplan, J.M. Herbert, C. Moore, H. Douglas, A. Wunderlich, and A.I. Braude. 1985. Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc. Natl. Acad. Sci. USA. 82:1790-1794.
11. Natanson, C., P.W. Eichenholtz, R.L. Danner, P.Q. Eichacker, W.D. Hoffman, G.C. Kuo, S.M. Banks, T.J. MacVittie, and J.E. Parillo. 1989. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J. Exp. Med. 169:823-832.
12. Okusawa, S., J.A. Gelfand, T. Ikejima, R.J. Connolly, and C.A. Dinarello. 1988. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J. Clin. Invest. 81:1162-1172.
13. Eichacker, P.Q., W.D. Hoffman, A. Farese, S.M. Banks, G.C. Kuo, T.J. MacVittie, and C. Natanson. 1991. Tumor necrosis factor but not interleukin-1 challenge in canines produces lethal pulmonary injury and sustained but reversible multiple organ dysfunction similar to human septic shock. J. Appl. Physiol. 71:1979-1989.
14. Smith, J.W. II, W.J. Urba, B.D. Curti, L.J. Elwood, R.G. Sties, J.E. Janik, W.H. Sharfman, L.L. Miller, F.G. Fenton, K.C. Conlon, et al. 1992. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J. Clin. Oncol. 10:1141-1152.
15. Suffredini, A.F., R.E. Fromm, M.M. Parker, M. Brenner, J.A. Kovacs, R.A. Wesley, and J.E. Parrillo. 1989. The cardiovascular response of normal humans to the administration of endotoxin. N. Engl. J. Med. 321:280-287.
16. Luce, J.M. 1993. Introduction of new technology into critical care practice: a history of monoclonal antibody against endotoxin. Crit. Care Med. 21: 1233-1241.
17. Dellinger, R.P. 1996. Post hoc analysis in sepsis trials: A formula for disappointment? Crit. Care Med. 24:727-729.
18. Novogrodsky, A., A. Vanichkin, M. Patya, A. Gazit, N. Osherov, and A. Levitzki. 1994. Prevention of lipopolysaccharide induced lethal toxicity by tyrosine kinase inhibitors. Science (Wash. DC). 264:1319-1322.
19. Yaish, P., A. Gazit, C. Gilon, and A. Levitzki. 1988. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science (Wash. DC). 242:933-935.
20. Glaser, K.B., A. Sung, J. Bauer, and B.M. Weichman. 1992. Regulation of eicosanoid biosynthesis in the macrophage. J. Biol. Chem. 265:8658-8664.
21. Dong, Z., C.A. O'Brian, and I.J. Fidler. 1993. Activation of tumoricidal properties in macrophages by lipopolysaccharide requires protein-tyrosine kinase activity. J. Leukocyte Biol. 53:53-60.
22. Vanichkin, A., M. Patya, A. Gazit, A. Levitzki, and A. Novogrodsky. 1996. Late administration of a lipophilic tyrosine kinase inhibitor prevents lipopolysaccharide and Escherichia coli induced lethal toxicity. J. Infect. Dis. 173: 927-933.
23. Guy, G.R., S.P. Chua, N.S. Wong, S.B. Ng, and Y.H. Tan. 1991. Interleukin 1 and tumor necrosis factor activate common multiple protein kinases in human fibroblasts. J. Biol. Chem. 266:14343-14352.
24. Natanson, C., M.P. Fink, H.K. Ballantine, T.J. MacVittie, J.J. Conklin, and J.E. Parrillo. 1986. Gram negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock. J. Clin. Invest. 78:259-270.
25. Natanson, C., R.L. Danner, R.J. Elin, J.M. Hosseini, K.W. Peart, S.M. Banks, T.J. MacVittie, R.I. Walker, and J.E. Parrillo. 1989. Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. J. Clin. Invest. 83:243-251.
26. Natanson, C., R.L. Danner, J.M. Reilly, M.I. Doerfler, W.D. Hoffman, G.L. Akin, J.M. Hosseini, S.M. Banks, R.J. Elin, T.J. MacVittie, and J.E. Parrillo. 1990. Antibiotics versus cardiovascular support in a canine model of human septic shock. Am. J. Physiol. 259:1440-1447.
27. Quezado, Z.M.N., C. Natanson, D.W. Ailing, S.M. Banks, C.A. Koev, R.J. Elin, J.M. Hosseini, J.D. Bacher, R.L. Danner, and W.D. Hoffman. 1993. A controlled trial of HA-1A in a canine model of gram-negative septic shock. JAMA. 269:2221-2227.
28. Gazit, A., P. Yaish, C. Gilon, and A. Levitzki. 1989. Tyrphostins I: synthesis and biological activity of protein tyrosine kinases. J. Med. Chem. 32: 2344-2352.
29. Gazit, A., N. Osherov, I. Posner, P. Yaish, E. Poradosa, C. Gilon, and A. Levitzki. 1991. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J. Med. Chem. 34:1896-1907.
30. Eichacker, P.Q., Y. Waisman, C. Natanson, A. Farese, W.D. Hoffman, S.M. Banks, and T.J. MacVittie. 1994. Cardiopulmonary effects of granulocyte colony stimulating factor in a canine model of sepsis. J. Appl. Physiol. 77(5): 2366-2373.
31. Bauer, P., and K. Kohne. 1994. Evaluation of experiments with adaptive interim analyses. Biometrics. 50:1029-1041.
32. Scheffe, H. 1959. The Analysis of Variance. John Wiley & Sons, New York. 55-137.
33. Lieberman, M.W., R. Barrios, B.Z. Carter, G.M. Habib, R.M. Lebovitz, S. Rajagopalan, A.R. Sepulveda, Z.Z. Shi, and D.F. Wan. 1995. γ-Glutamyl transpeptidase. Am. J. Pathol. 147:1175-1185.
34. Natanson, C., W.D. Hoffman, C.A. Koev, D.P. Dolan, S.M. Banks, J. Bacher, R.L. Danner, H.G. Klein, and J.E. Parrillo. 1993. Plasma exchange does not improve survival in a canine model of septic shock. Transfusion (Bethesda). 33:243-248.
35. Quezado, Z.M.N., C. Natanson, S.M. Banks, C.A. Koev, R.L. Danner, R.J. Elin, J.H. Hosseini, J.D. Bacher, and W.D. Hoffman. 1993. Pentoxifyllene can increase tumor necrosis factor level and decrease survival in a canine model of gram negative septic shock. Crit. Care Med. 21(Suppl.):281.
36. Freeman, B.D., I. Yatsiv, C. Natanson, M.A. Solomon, Z.M.N. Quezado, R.L. Danner, S.M. Banks, and W.D. Hoffman. 1995. Continuous arteriovenous hemofiltration does not improve survival in a canine model of septic shock. J. Am. Coll. Surg. 180:286-292.
37. Quezado, Z.M.N., C. Natanson, W.D. Hoffman, W. Karzai, C.A. Koev, R.L. Danner, S.M. Banks, L. Wilson, and P.Q. Eichacker. 1995. Granulocyte colony stimulating factor(G-CSF) treatment at the onset of E. coli induced septic shock in canines. Am. J. Respir. Crit. Care Med. 151:447a. (Abstr.)
38. Eichacker, P.Q., W.D. Hoffman, A. Farese, R.L. Danner, A.F. Suffredini, Y. Waisman, S.M. Banks, L. Wilson, R. Rothlein, R.J. Elin, J.M. Hosseini, T.J. MacVittie, and C. Natanson. 1993. Antibody against leucocyte CD-18 adhesion complex worsens endotoxemia and cardiovascular dysfunction in antibiotic treated canines with septic shock. J. Appl. Physiol. 74:1885-1892.
39. Hoffman, W.D., M. Pollack, S.M. Banks, C.A. Koev, M.A. Solomon, R.L. Danner, N. Koles, G. Guelde, I. Yatsiv, T. Mouganis, et al. 1994. Distinct functional activities in canine septic shock of monoclonal antibodies specific for the O-polysaccharide and core regions of Escherichia coli lipopolysaccharide. J. Infect. Dis. 169:553-561.